NIKI (Niki BioSolutions) ROIC %: -17.81% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIKI Niki BioSolutions Inc NIKI
56 GF Score
Price $8.83
GF Value $11.69
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Niki BioSolutions ROIC %?

Niki BioSolutions NIKI -7.49% 56 ROIC % is -17.81% as of Dec. 2025. GuruFocus rates NIKI with a GF Score™ of 56/100 and a GF Value™ of $11.69 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Niki BioSolutions's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was -17.81%.

As of today (2026-07-22), Niki BioSolutions's WACC % is -5.25%. Niki BioSolutions's ROIC % is -8.00% (calculated using TTM income statement data). Niki BioSolutions earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Niki BioSolutions  (NAS:NIKI) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Niki BioSolutions's WACC % is -5.25%. Niki BioSolutions's ROIC % is -8.00% (calculated using TTM income statement data). Niki BioSolutions earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Niki BioSolutions ROIC % Related Terms


Niki BioSolutions ROIC % Historical Data

* Premium members only.

The historical data trend for Niki BioSolutions's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niki BioSolutions ROIC % Chart

Niki BioSolutions Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only -187.68 -116.30 -55.20 -16.32 -9.81

Niki BioSolutions Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.02 12.08 0.00 -14.01 -17.81

NIKI vs LABT, NCNA, SNGX: ROIC % Comparison

For the Biotechnology subindustry, Niki BioSolutions's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Niki BioSolutions ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Niki BioSolutions's ROIC % distribution charts can be found below:

* The bar in red indicates where Niki BioSolutions's ROIC % falls into.


NIKI
56GF Score
Niki BioSolutions Inc NIKI
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niki BioSolutions ROIC % Calculation

Niki BioSolutions's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-1.818 * ( 1 - 0% )/( (18.511 + 18.541)/ 2 )
=-1.818/18.526
=-9.81 %

where

Niki BioSolutions's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-3.3 * ( 1 - 0% )/( (18.524 + 18.541)/ 2 )
=-3.3/18.5325
=-17.81 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -17.81% mean?
Niki BioSolutions (NIKI) has a ROIC % of -17.81% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Niki BioSolutions and its competitors.
Is Niki BioSolutions' ROIC % too high?
Niki BioSolutions' current ROIC % is -17.81%. Overall, Niki BioSolutions has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Niki BioSolutions' ROIC % compare to LABT and NCNA?
Niki BioSolutions' ROIC % of -17.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Niki BioSolutions and its competitors. Niki BioSolutions's current ROIC % is -17.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niki BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Niki BioSolutions (NIKI) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.69, compared to a current price of $8.83 — trading 24.5% below its estimated fair value. The current ROIC % is -17.81%. Niki BioSolutions' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Niki BioSolutions (NIKI), the current ROIC % is -17.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Niki BioSolutions (NIKI) Overvalued in 2026?

Based on GuruFocus' analysis, Niki BioSolutions stock appears to be undervalued. The current stock price of $8.83 is trading 24.5% below its estimated GF Value™ of $11.69. GuruFocus considers Niki BioSolutions to be Modestly Undervalued.

Key valuation signals for NIKI:

  • ROIC %: -17.81%
  • GF Value™: $11.69 vs. price of $8.83 (24.5% below fair value)
  • GF Score™: 56/100 with 1 warning sign

No single metric tells the full story. See the NIKI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Niki BioSolutions Business Description

Address 17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
56GF Score

Get the complete analysis for NIKI

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.83
Price
$11.69
GF Value